A PET-CT scan can find cancer that other tests miss — and it does so by watching how tissue behaves, not just how it looks. By fusing a metabolic map of the body with a detailed anatomical picture in a single session, PET-CT helps doctors detect tumours, judge how far a cancer has spread, and check whether treatment is working. Here is how the technology works, what it can reveal, and how patients can access it through Medical E-Aid.

What is a PET-CT scan?

PET-CT combines two imaging technologies in one machine. Positron emission tomography (PET) shows the body’s physiology — how active tissue is metabolically. Computed tomography (CT) shows anatomy — the precise size, shape and location of organs and masses. On their own, each has limits; fused together, they let a radiologist see an area of abnormal activity and pinpoint exactly where it sits in the body.

The scan relies on a small amount of a radioactive tracer. The most common is 18F-fluorodeoxyglucose (FDG), a glucose-like molecule tagged with a short-lived radioactive marker. Because many cancer cells consume glucose far faster than normal tissue, they take up more FDG — and light up brightly on the PET image.

How PET-CT works

The principle is elegantly simple. Tumour cells are metabolically hungry, so they absorb the FDG tracer preferentially. As the tracer decays, it emits signals that the PET detector captures, building a three-dimensional map of where metabolic activity is highest. The CT component, acquired moments later in the same machine, overlays that map onto crisp anatomical images.

The result is a fused picture in which a suspicious “hot spot” can be located to the millimetre. This is why PET-CT is often better than CT alone at determining nodal status and uncovering occult metastatic disease — small deposits of cancer that have not yet changed the size or shape of an organ and would be invisible on anatomy-only imaging.

What PET-CT is used for

PET-CT has become a cornerstone of modern oncology across a wide range of cancers. Its main roles include:

• Detecting and characterising tumours — distinguishing metabolically active (often malignant) tissue from benign findings.
• Staging — mapping how far a cancer has spread to lymph nodes and distant organs, which directly shapes the treatment plan.
• Restaging and monitoring — assessing whether a tumour is responding to chemotherapy, radiation or immunotherapy.
• Detecting recurrence — finding cancer that has returned after treatment, sometimes before symptoms appear.
• Guiding radiotherapy — helping radiation oncologists define the precise target volume.

It is widely applied in lung, head and neck, lymphoma, oesophageal, colorectal, cervical and breast cancers, among others.

How accurate is it?

Accuracy depends heavily on the cancer type and what is being assessed, but the figures reported in peer-reviewed studies are compelling. In lymph-node staging of lung cancer, one published analysis reported a sensitivity around 91% and specificity around 94%, with overall accuracy above 90%. In head and neck cancer, a meta-analysis found roughly 89% sensitivity and 94% specificity for detecting distant disease. Performance is more modest in some settings — for example, in regions where tuberculosis or inflammation can mimic tumour activity — which is exactly why PET-CT is interpreted alongside other tests rather than used in isolation. The consistent theme across the literature is that adding PET to CT frequently changes the stage assigned to a cancer, and with it the treatment decision.

The benefits at a glance

• Whole-body view — a single scan surveys the entire body for disease.
• Metabolic insight — detects active cancer before it visibly changes an organ’s anatomy.
• Better staging — often reveals spread that CT or MRI alone would miss, avoiding under- or over-treatment.
• Non-invasive — no surgery; the tracer is given through a small IV line.
• Response tracking — shows whether a therapy is working, allowing earlier course-correction.

What to expect

Preparation is straightforward but important. Patients are usually asked to avoid strenuous exercise for 24 hours and to fast for several hours before the tracer injection, because food raises blood sugar and can compete with the FDG. Blood glucose is checked first — well-controlled levels give the clearest images, which matters especially for patients with diabetes.

The tracer is injected through a small IV line, followed by a quiet rest period of roughly an hour while it distributes through the body. The scan itself is painless: you lie still while the machine acquires images, typically over 30 to 90 minutes. The amount of radiation is low, and the tracer clears from the body within hours; drinking water helps flush it out. Most people return to normal activity the same day.

Accessing PET-CT with Medical E-Aid

PET-CT is available only at centres with nuclear-medicine facilities and on-site or nearby tracer production. Medical E-Aid connects patients with leading, internationally equipped diagnostic and cancer centres and coordinates the whole journey — a medical review of your case, the right imaging and specialist referrals, cost estimates, and full support with travel, visas, interpretation and aftercare. Our AI pre-screening helps match your specific situation to the appropriate specialist and centre, so the diagnostic pathway is efficient from the very first step.

This article is for general information only and is not medical advice. Whether PET-CT is appropriate depends on each patient’s diagnosis and must be determined by qualified specialists. Accuracy and outcome figures are drawn from published clinical studies and may not reflect individual results.

Sources: StatPearls / NCBI Bookshelf, “PET Scanning” (National Library of Medicine); “Diagnostic Accuracy of FDG PET-CT in Lymph Nodal Staging of Lung Cancer,” PMC (2025); “18F-FDG PET/CT Imaging in Oncology,” PMC; “Use of FDG PET for Staging and Re-Staging of Head and Neck Squamous Cell Carcinoma,” Cancers (2025); LACOG 0114 diagnostic test study, PMC.